pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,923 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1172Endpoints885BioPharma Dive340BioSpace307Fierce Biotech287onclive165raps104globenewswire health73
therapy area
allOncology7528Rare Disease1860Cardiology1714Immunology1473Hematology1317Vaccines1195Pulmonology
  • FDA Commissioner Marty Makary Ousted After Trump-Backed Action
    The piece reports that Marty Makary, who had been serving as FDA commissioner, is no longer in the role. His removal came after headlines emerged that President Donald Trump had signed a measure…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Lakefront Biotherapeutics rebrands from Galapagos as it seeks turnaround from Chicago office
    Lakefront Biotherapeutics, formerly known as Galapagos, announced a rebranding effort aimed at reviving the company’s fortunes. The change reflects a strategic shift as the firm looks to reposition…
    Endpoints · 3mo agoNeutral↗ source
← prev
page 69 of 77
next →
fda recalls67
fda medwatch60
fda press38
1145
Psychiatry & CNS866
Ophthalmology494
Pain478
Endocrinology & Metabolism468
Infectious Disease444
  • Isomorphic Labs secures $2.1 billion Series B, cementing AI drug-discovery leadership
    Isomorphic Labs announced on Tuesday that it has closed a $2.1 billion Series B financing round. The sizable round underscores the company’s position as a bellwether for using artificial intellige…
    Endpoints · 3mo agoDealPositive↗ source
  • Bristol Myers Squibb partners with Hengrui Pharma in $15.2 billion, 13-asset deal
    Bristol Myers Squibb announced a partnership with China’s Hengrui Pharma that includes 13 assets. The transaction is reported to be valued at up to $15.2 billion, highlighting the scale of collabo…
    Endpoints · 3mo agoDealNeutral↗ source
  • FDA chief Marty Makary resigns, ending turbulent tenure
    FDA chief Marty Makary has resigned, ending a tenure described as turbulent with leadership upheaval, mass layoffs, political pressure and public disputes with drugmakers. President Trump announce…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • Bristol Myers Squibb and China's Hengrui Pharma launch $15.2 billion alliance covering up to 13 early-stage drugs
    Bristol Myers Squibb announced a new partnership with Chinese drugmaker Hengrui Pharma that could be worth more than $15.2 billion and includes up to 13 early-stage drug candidates. The deal refle…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Serif Biomedicines claims breakthrough in non-viral gene therapy demonstrated in monkeys
    Serif Biomedicines, a startup launched by Flagship Pioneering last month, announced it believes it has overcome two key technical hurdles that have limited non-viral gene therapy. The company says…
    Endpoints · 3mo agoPositive↗ source
  • Alkermes reports Phase 3 success for Lumryz; Boehringer announces antibody partnership
    Alkermes announced that its narcolepsy medication Lumryz, which received regulatory approval in 2023, achieved its primary efficacy endpoint in a Phase 3 trial. The study met the predefined criter…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Pain drug research gains momentum a year after Vertex launch as new startups revive sodium channel targets
    A year after Vertex introduced its breakthrough pain medication, the field of pain drug development is at a pivotal crossroads. Analysts note that renewed scientific focus and investor interest are…
    BioPharma Dive · 3mo agoPositive↗ source
  • Eli Lilly suggests low-dose Zepbound and Foundayo could safely maintain weight loss at lower cost
    New trial data indicate that lowering the dose of Eli Lilly's obesity injection Zepbound may still provide effective weight‑loss maintenance while improving safety. The study also highlights Found…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • EU Parliament and Council provisionally approve Critical Medicines Act to strengthen drug supply chains
    The European Parliament and the Council have provisionally voted to adopt the Critical Medicines Act, marking a key step toward its implementation. The legislation is designed to reinforce the EU’…
    Endpoints · 3mo agoRegulatoryPositive↗ source
  • Iran war disruptions ripple through pharma supply chain, raising raw material and shipping costs
    The ongoing conflict between Iran and its adversaries has entered its third month, and analysts are now seeing early signs that the fighting is affecting the pharmaceutical supply chain. Disruptio…
    Endpoints · 3mo agoNegative↗ source
  • Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel Pharmaceuticals
    Arvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Pfizer, Arvinas sell recently approved breast cancer drug to Rigel for $35 million
    Pfizer and its partner Arvinas have agreed to transfer the commercial rights of a breast cancer therapy to Rigel Pharmaceuticals. The drug had just received regulatory approval, marking a mileston…
    Endpoints · 3mo agoDealNegative↗ source
  • Bayer signals cautious yet aggressive push into pharma acquisitions after five-year pause
    Bayer's CEO Bill Anderson told investors on the first-quarter earnings call that the company is ready to re-enter the pharmaceutical merger-and-acquisition market after a five-year hiatus. He emph…
    Endpoints · 3mo agoDealPositive↗ source
  • Knit Health secures $11.6M seed round to develop doctor-like AI for healthcare operations
    Knit Health, a startup spun out of UC Berkeley, announced it has closed a seed financing round of $11.6 million. The round was co‑led by Uncork Capital, providing the capital the company plans to…
    Endpoints · 3mo agoDealPositive↗ source
  • FDA Commissioner Marty Makary steps down after weeks of uncertainty
    Marty Makary, the commissioner of the U.S. Food and Drug Administration, announced his resignation on Tuesday. The decision came after his employment status was uncertain for several days, accordi…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Journalist reflects on challenges of reporting healthcare AI after fellowship
    The author participated in a journalism fellowship that focused on health technology reporting. The experience underscored the importance of continuously examining the incentives that drive AI pro…
    Endpoints · 3mo agoNeutral↗ source
  • CSL shares plunge to nine-year low after cutting revenue forecast and announcing $5 billion impairment
    CSL's shares fell to their lowest level since early 2017 after the company reduced its full‑year revenue guidance by roughly four percent. The guidance cut signals slower sales growth than previous…
    Endpoints · 4mo agoEarningsNegative↗ source
  • Rezdiffra Beats Wall Street Forecasts as MASH Market Expands
    Rezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
    Endpoints · 3mo agoPositive↗ source
  • Inhibrx reports 44% response rate when paired with Keytruda in head-and-neck cancer Phase 2 trial
    Inhibrx Biosciences said its experimental agent INBRX-106 boosted the activity of Merck's Keytruda in a Phase 2 study of a head-and-neck cancer. The combination achieved a 44% overall response rate…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • GSK partners with Sino Biopharma to expand access to hepatitis B drug bepirovirsen in China
    GSK announced a marketing agreement with Sino Biopharmaceutical to distribute its experimental hepatitis B therapy bepirovirsen in China. Sino's subsidiary will purchase a supply of the drug and u…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Daiichi Sankyo targets $15 billion in oncology sales by 2030 as it expands ADC franchise
    Daiichi Sankyo released a new five‑year business plan that sets a goal of nearly $15 billion in oncology revenue by 2030. The target is part of a broader ambition to push total company sales past 3…
    Endpoints · 3mo agoNeutral↗ source
  • Inhibrx reports combo of Keytruda and INBRX-106 reduces tumors more than Keytruda alone in metastatic head cancer
    San Diego biotech Inhibrx says its experimental drug INBRX-106, when added to Merck's immunotherapy Keytruda, led to a higher rate of tumor shrinkage than Keytruda by itself. The observation comes…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial results
    Braveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial. The mid-stage study met its primary endpo…
    Endpoints · 4mo agoPositive readoutPositive↗ source